Curis Lifesciences Limited
Curis Lifesciences disclosed that Rs. 7.75 crore (28%) of its Initial Public Offering funds raised in November 2025 remain unutilized as of March 31, 2026. These funds were allocated for capital expenditure towards manufacturing facilities and a storage facility, as well as product registrations.
May 30 2026 21:20:38
Curis Lifesciences Limited
Curis Lifesciences board will meet on May 30, 2026, to consider and approve its audited annual financial results for the year ended March 31, 2026. This meeting will finalize the company's financial performance for the last fiscal year.
May 26 2026 13:17:20
Curis Lifesciences Limited
Curis Lifesciences board will convene on May 30, 2026, to review and approve the audited standalone financial results for the fiscal year ended March 31, 2026. The meeting will also cover the utilization of IPO proceeds.
May 26 2026 13:15:01
Eris Lifesciences Limited
Eris Lifesciences Limited declared an interim dividend of Rs. 7.21 per equity share for the financial year 2026-27. The record date for this dividend is May 29, 2026, with payment to be made by June 19, 2026.
May 20 2026 15:04:12
Eris Lifesciences Limited
Eris Lifesciences' subsidiary Eris Therapeutics had its bank loan facilities rated 'IND AA/Stable/IND A1+' by India Ratings. This includes a new assignment for INR 100 crore and affirmation for INR 420 crore, which was reduced from INR 469 crore.
May 12 2026 19:23:43
Eris Lifesciences Limited
India Ratings and Research (Ind-Ra) affirmed Eris Lifesciences's Long-term Issuer Rating and bank facilities at 'IND AA' with a Stable Outlook. This reflects the company's sustained healthy operating performance.
May 08 2026 17:05:28
Read More